Liquid Biopsies in Non-CNS Malignant Pediatric Solid Tumors

PRIMARY OBJECTIVES:

I. To determine the feasibility of detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating tumor RNA (ctRNA) in serial blood samples from patients with newly diagnosed and relapsed/refractory malignant pediatric solid tumors.

II. To evaluate the kinetics of ctDNA and CTCs in patients with newly diagnosed and relapsed/refractory pediatric solid tumors during therapy (including the perioperative period) and after completion of therapy and correlate these findings with response by conventional methods (e.g., imaging studies, histologic tumor response, and serum tumor markers) and outcome.

III. To compare the ctDNA profile with the genetic profile of the primary, metastatic or recurrent tumor, if available.

IV. To compare different assays for the detection of ctDNA in patients with osteosarcoma, Ewing sarcoma, synovial sarcoma, and rhabdomyosarcoma.

V. To explore whether RNA or DNA isolated from tumor-derived exosomes from cancer patients differs from that of healthy controls and correlates with tumor response, relapse, and outcome.

VI. To explore differences in DNA isolated from tumor-derived exosomes from plasma and ctDNA in patients with osteosarcoma.

VII. To bank leftover plasma samples for future studies.

OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.

GROUP I (CANCER PATIENTS): Patients undergo blood sample collection and have their medical records reviewed throughout the study.

GROUP II (HEALTHY CONTROL SUBJECTS): Healthy participants undergo a one time blood sample collection on study.